Literature DB >> 21389281

Prevalence of MRI-defined recent silent ischemia and associated bleeding risk with thrombolysis.

M Tisserand1, L Le Guennec, E Touzé, A Hess, C Charbonnier, A-D Devauchelle, S Bracard, J-L Mas, J-F Méder, C Oppenheim.   

Abstract

BACKGROUND: Uncertainties about the frequency and the associated bleeding risk of recent silent ischemia (RSI), incidentally found on pretreatment MRI, in candidates for thrombolysis require clarification because exclusion from therapy is a serious consequence for patients with such MRI findings.
METHODS: We retrospectively analyzed the fluid-attenuated inversion recovery (FLAIR)/diffusion-weighted imaging (DWI) obtained before IV thrombolysis in 115 patients to search for MRI-defined RSI; these corresponded to well-developed FLAIR/DWI brain hyperintensities (RSI+), as distinct from the acute index ischemia, which typically lacked FLAIR changes. Patients without such findings were assigned to the RSI- group. Groups were compared for baseline characteristics and for rates of symptomatic and asymptomatic hemorrhagic transformation (HT) using odds ratios (OR) and their 95%confidence intervals (CI).
RESULTS: We observed RSI in 21 patients (18.3%). The mean (SD) volume of RSI was 6.5 (12) mL (interquartile range 0.6-9). None of the baseline parameters differed between groups. There was no significant difference in rates of any type of HT between groups. Parenchymal hemorrhage type 1 or type 2 according to European Cooperative Acute Stroke Study criteria occurred in 2 (10%) RSI+ patients and in 10 (11%) RSI- patients (OR 0.88; 95% CI 0.18-4.37). Symptomatic HT, defined according to National Institute of Neurological Disorders and Stroke criteria, occurred in 1 (5%) RSI+ patient and in 10 (11%) RSI- patients (OR 0.42; 95% CI 0.05-3.47).
CONCLUSIONS: We found that 18.3% of patients with acute stroke treated by IV thrombolysis in a stroke unit had RSI on pretreatment MRI. However, the presence of RSI was not associated with an increased risk of asymptomatic or symptomatic HT.

Entities:  

Mesh:

Year:  2011        PMID: 21389281     DOI: 10.1212/WNL.0b013e3182152855

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  3 in total

1.  Safety of intravenous tissue plasminogen activator administration with computed tomography evidence of prior infarction.

Authors:  Michael J Lyerly; J Thomas Houston; Amelia K Boehme; Karen C Albright; Reza Bavarsad Shahripour; Paola Palazzo; Muhammed Alvi; Pawan V Rawal; Niren Kapoor; April Sisson; Anne W Alexandrov; Andrei V Alexandrov
Journal:  J Stroke Cerebrovasc Dis       Date:  2014-03-28       Impact factor: 2.136

2.  Exploring Contraindications for Thrombolysis: Risk of Hemorrhagic Transformation and Neurological Deterioration after Thrombolysis in Mice with Recent Ischemic Stroke and Hyperglycemia.

Authors:  Sarah Gelhard; Roxane-Isabelle Kestner; Moritz Armbrust; Helmuth Steinmetz; Christian Foerch; Ferdinand O Bohmann
Journal:  J Clin Med       Date:  2022-06-10       Impact factor: 4.964

3.  T2* "susceptibility vessel sign" demonstrates clot location and length in acute ischemic stroke.

Authors:  Olivier Naggara; Jean Raymond; Montserrat Domingo Ayllon; Fawaz Al-Shareef; Emmanuel Touzé; Meriem Chenoufi; Sophie Gerber; Charles Mellerio; Matthieu Zuber; Jean Francois Meder; Jean-Louis Mas; Catherine Oppenheim
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.